COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,577 Articles (22,415 medRxiv, 8,162 bioRxiv)

Most recent first Previous |  Page 2168: Articles 21671-21680  | Next

SARS-CoV-2 PCR cycle threshold at hospital admission associated with Patient Mortality
Choudhuri, J., Carter, J., Nelson, R., Skalina, K., Osterbur-Badhey, M., Johnson, A., Goldstein, D. Y., Paroder, M., Szymanski, J.
10.1101/2020.09.16.20195941 — Posted: 2020-09-20 Discussion: Onsite | Offsite
Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays
Belda, F., Cherenzia, R., Crowley, M.
10.1101/2020.09.08.20190256 — Posted: 2020-09-20
SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic.
Favara, D. M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Doffinger, R., Ainsworth, N., Corrie, P.
10.1101/2020.09.18.20197590 — Posted: 2020-09-20
Suppression of COVID-19 infection by isolation time control based on the SIR model and an analogy from nuclear fusion research
Mitarai, O., Yanagi, N.
10.1101/2020.09.18.20197723 — Posted: 2020-09-20
Antisense oligonucleotides target a nearly invariant structural element from the SARS-CoV-2 genome and drive RNA degradation
Lulla, V., Wandel, M. P., Bandyra, K. J., Dendooven, T., Yang, X., Doyle, N., Oerum, S., O'Rourke, S., Randow, F., Maier, H. J., Scott, W., Ding, Y., Firth, A., Bloznelyte, K., Luisi, B.
10.1101/2020.09.18.304139 — Posted: 2020-09-19 Discussion: Onsite | Offsite
An immunodominance hierarchy exists in CD8+ T cell responses to HLA-A*02:01-restricted epitopes identified from the non-structural polyprotein 1a of SARS-CoV-2.
Takagi, A., Matsui, M.
10.1101/2020.09.18.304493 — Posted: 2020-09-19
Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Peru
Chiara-Chilet, C., Luna-Vilchez, M., Maquera-Afaray, J., Salazar-Mesones, B., Portillo-Alvarez, D., Priale-Miranda, R., Mendoza-Torres, F., Munayco-Perez, A., Baca-Cama, Y., Santiago-Abad, M., Lopez, J. W., Pediatric COVID-19 Working Group INSN SB
10.1101/2020.09.18.20186866 — Posted: 2020-09-18
Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes
Ulyte, A., Radtke, T., Abela, I. A., Haile, S. H., Blankenberger, J., Jung, R., Capelli, C., Berger, C., Frei, A., Huber, M., Schanz, M., Schwarzmueller, M., Trkola, A., Fehr, J., Puhan, M. A., Kriemler, S.
10.1101/2020.09.18.20191254 — Posted: 2020-09-18
SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia
Tsertsvadze, T., Gatserelia, L., Mirziashvili, M., Dvali, N., Abutidze, A., Metchurtchlishvili, R., del Rio, C., Chkhartishvili, N.
10.1101/2020.09.18.20195024 — Posted: 2020-09-18
IMPACT OF UNIVERSITY RE-OPENING ON TOTAL COMMUNITY COVID-19 BURDEN
Cipriano, L. E., Haddara, W. M. R., Zaric, G. S., Enns, E. A.
10.1101/2020.09.18.20197467 — Posted: 2020-09-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).